The urinary and prostatic microbiome in non-neurogenic male LUTS/BPH: A systematic review
- PMID: 38934484
- DOI: 10.1002/nau.25530
The urinary and prostatic microbiome in non-neurogenic male LUTS/BPH: A systematic review
Abstract
Introduction: Despite advancements in the treatment of benign prostatic hyperplasia (BPH), the mechanisms underlying BPH development and progression remain elusive and lacks a one-size-fits-all therapeutic solution. Prostatic inflammation contributes to BPH and lower urinary tract symptoms (LUTS), but the initial trigger remains unknown. Current research suggests dysbiosis of the urinary microbiome as a potential culprit. This systematic review explores the emerging field of the male urinary and prostatic microbiome and its relationship with BPH/LUTS.
Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. A systematic search in the Pubmed and Scopus databases was performed using specific terms. Inclusion criteria considered male non-neurogenic patients with LUTS due to BPH with analyses of urinary microbiome, concerning evaluation of English-language publications with relevance.
Results: Among seven articles involving 542 patients, there was an association between male LUTS/BPH and the urinary microbiome. Findings indicate a correlation between urinary microbiome dysbiosis and LUTS severity, with specific bacterial genera such as Streptococcus and Haemophilus linked to higher International Prostate Symptom Score (IPSS) scores and PSA levels. The fecal microbiome may be associated with LUTS, although contradictory findings are reported. The review also highlights methodological inconsistencies, small sample sizes, few negative controls and a lack of comprehensive clinical data as major limitations.
Conclusions: While there is an undeniable correlation between the microbiome and LUTS/BPH, future research should aim to standardize sampling techniques and expand the score to include functional microbiome characterization, potentially leading to novel, microbiome-targeted therapeutic strategies for BPH.
Keywords: benign prostatic enlargement; benign prostatic hyperplasia; lower urinary tract dysfunction; lower urinary tract symptoms; microbiome; microbiota.
© 2024 Wiley Periodicals LLC.
Similar articles
-
The impact of urine microbiota in patients with lower urinary tract symptoms.Ann Clin Microbiol Antimicrob. 2021 Apr 15;20(1):23. doi: 10.1186/s12941-021-00428-9. Ann Clin Microbiol Antimicrob. 2021. PMID: 33858430 Free PMC article.
-
The role of the urinary microbiome on male benign prostatic hyperplasia (BPH) and its management using probiotic supplementation: a narrative review.Eur Rev Med Pharmacol Sci. 2024 Dec;28(23):4671-4679. doi: 10.26355/eurrev_202412_36978. Eur Rev Med Pharmacol Sci. 2024. PMID: 39687970 Review.
-
Urine chemokines indicate pathogenic association of obesity with BPH/LUTS.Int Urol Nephrol. 2015 Jul;47(7):1051-8. doi: 10.1007/s11255-015-0992-2. Epub 2015 Apr 30. Int Urol Nephrol. 2015. PMID: 25924782 Free PMC article.
-
Association of increased urine brain derived neurotrophic factor with lower urinary tract symptoms in men with benign prostatic hyperplasia.J Huazhong Univ Sci Technolog Med Sci. 2017 Aug;37(4):531-535. doi: 10.1007/s11596-017-1768-y. Epub 2017 Aug 8. J Huazhong Univ Sci Technolog Med Sci. 2017. PMID: 28786061
-
Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.BJU Int. 2018 Dec;122(6):1049-1065. doi: 10.1111/bju.14362. Epub 2018 Jun 6. BJU Int. 2018. PMID: 29694707
Cited by
-
Insights into the Interplay between the Urinary Microbiome and Bladder Cancer: A Comprehensive Review.J Clin Med. 2024 Aug 21;13(16):4927. doi: 10.3390/jcm13164927. J Clin Med. 2024. PMID: 39201069 Free PMC article. Review.
References
REFERENCES
-
- Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) ‐ focus on the UK. BJU Int. 2015;115(4):508‐519.
-
- Abrams P. LUTS, BPH, BPE, BPO: a plea for the logical use of correct terms. Rev Urol. 1999;1(2):65.
-
- Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Rittmaster RS, Somerville MC. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54(1379‐84):1379‐1384.
-
- Roehrborn CG, Kaplan SA, Noble WD, et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results fromthe MTOPS study. J Urol. 2005;173(4S):346.
-
- De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011;60(1):106‐117.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous